Teresa Gamucci

8.6k total citations
128 papers, 3.5k citations indexed

About

Teresa Gamucci is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Teresa Gamucci has authored 128 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Teresa Gamucci's work include Cancer Treatment and Pharmacology (43 papers), Colorectal Cancer Treatments and Studies (30 papers) and Breast Cancer Treatment Studies (23 papers). Teresa Gamucci is often cited by papers focused on Cancer Treatment and Pharmacology (43 papers), Colorectal Cancer Treatments and Studies (30 papers) and Breast Cancer Treatment Studies (23 papers). Teresa Gamucci collaborates with scholars based in Italy, Malaysia and United Kingdom. Teresa Gamucci's co-authors include Laura Biganzoli, Robert E. Coleman, Jaap Verweij, Patrizia Vici, J. Wanders, Martine Piccart, Laura Pizzuti, Andrea Ardizzoni, Clara Natoli and P.F. Bruning and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Teresa Gamucci

126 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Teresa Gamucci Italy	28	2.3k	827	723	688	482	128	3.5k
Jean‐Paul Guastalla France	31	2.2k 0.9×	621 0.8×	674 0.9×	495 0.7×	284 0.6×	109	3.7k
P. Pronzato Italy	32	2.5k 1.1×	731 0.9×	1.1k 1.5×	884 1.3×	887 1.8×	231	4.4k
Patrizia Vici Italy	34	1.9k 0.8×	867 1.0×	782 1.1×	680 1.0×	255 0.5×	206	3.6k
F. Cavalli Switzerland	33	2.2k 0.9×	705 0.9×	652 0.9×	660 1.0×	322 0.7×	147	4.0k
N. Tubiana-Mathieu France	30	2.0k 0.9×	436 0.5×	630 0.9×	644 0.9×	186 0.4×	166	3.2k
Edgar Petru Austria	33	1.5k 0.6×	691 0.8×	897 1.2×	898 1.3×	165 0.3×	222	3.9k
Wayne Rackoff United States	19	1.0k 0.4×	766 0.9×	362 0.5×	945 1.4×	127 0.3×	35	2.9k
Tom Anderson United States	32	1.6k 0.7×	730 0.9×	278 0.4×	820 1.2×	217 0.5×	88	3.7k
Roshan Agarwal United Kingdom	30	1.1k 0.5×	1.7k 2.0×	716 1.0×	479 0.7×	606 1.3×	61	3.8k
Lindsey Gumbrell United Kingdom	17	1.3k 0.6×	932 1.1×	274 0.4×	564 0.8×	144 0.3×	24	2.7k

Countries citing papers authored by Teresa Gamucci

Since Specialization

Citations

This map shows the geographic impact of Teresa Gamucci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teresa Gamucci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teresa Gamucci more than expected).

Fields of papers citing papers by Teresa Gamucci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teresa Gamucci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teresa Gamucci. The network helps show where Teresa Gamucci may publish in the future.

Co-authorship network of co-authors of Teresa Gamucci

This figure shows the co-authorship network connecting the top 25 collaborators of Teresa Gamucci. A scholar is included among the top collaborators of Teresa Gamucci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teresa Gamucci. Teresa Gamucci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Ippolito, Edy, Paolo Matteucci, Carlo Greco, et al.. (2022). Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series. Cancers. 14(2). 303–303. 4 indexed citations

2.

Nelli, Fabrizio, Agnese Fabbri, Luca Moscetti, et al.. (2020). Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. Recenti Progressi in Medicina. 111(12). 761–768. 2 indexed citations

3.

Mennini, Francesco Saverio, Andrea Marcellusi, Alessandro Giunta, et al.. (2019). The economic impact of biosimilars in Italy: a scenario analysis. SHILAP Revista de lepidopterología. 6(1). 2 indexed citations

4.

Krasniqi, Eriseld, Giacomo Barchiesi, Laura Pizzuti, et al.. (2019). Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. Journal of Hematology & Oncology. 12(1). 111–111. 96 indexed citations

5.

Grassadonia, Antonino, Isabella Sperduti, Patrizia Vici, et al.. (2018). Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. Preprints.org. 1 indexed citations

6.

Grassadonia, Antonino, Isabella Sperduti, Patrizia Vici, et al.. (2018). Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. Preprints.org. 20 indexed citations

7.

Moscetti, Luca, Lucia Mentuccia, Patrizia Vici, et al.. (2017). ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. Future Oncology. 13(17). 1517–1525. 4 indexed citations

8.

Ercolani, Cristiana, Anna Di Benedetto, Irene Terrenato, et al.. (2017). Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. Cancer Biology & Therapy. 18(5). 339–346. 15 indexed citations

9.

Barba, Maddalena, Patrizia Vici, Laura Pizzuti, et al.. (2017). Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer. 17(1). 101–101. 7 indexed citations

10.

Sini, Valentina, Alessandra Cassano, Domenico Corsi, et al.. (2016). Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons. Tumori Journal. 102(5). 472–480. 13 indexed citations

11.

Puglisi, Fabio, Giancarlo Bisagni, Mariangela Ciccarese, et al.. (2016). A Delphi Consensus and Open Debate on the Role of First-Line Bevacizumab for HER2-Negative Metastatic Breast Cancer. Future Oncology. 12(22). 2589–2602. 5 indexed citations

12.

Vici, Patrizia, Marcella Mottolese, Laura Pizzuti, et al.. (2014). The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget. 5(20). 9619–9625. 31 indexed citations

13.

Grande, Roberta, Isabella Sperduti, Alain Gelibter, et al.. (2013). Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?. SpringerPlus. 2(1). 185–185. 1 indexed citations

14.

Gamucci, Teresa, Luca Moscetti, Lucia Mentuccia, et al.. (2013). Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients. Journal of Cancer Research and Clinical Oncology. 140(2). 221–226. 8 indexed citations

15.

Gori, Stefania, Matteo Clavarezza, Salvatore Siena, et al.. (2012). Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer. 12(1). 158–158. 12 indexed citations

16.

Gridelli, Cesare, Ciro Gallo, Alessandro Morabito, et al.. (2011). Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. Journal of Thoracic Oncology. 7(1). 233–242. 5 indexed citations

17.

Metro, Giulio, Diana Giannarelli, Gaetano Lanzetta, et al.. (2009). Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer. The Breast Journal. 16(1). 66–72. 10 indexed citations

18.

Atalay, G., Laura Biganzoli, Françoise Renard, et al.. (2002). Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era. UCL Discovery (University College London). 1 indexed citations

19.

Serrone, L., Massimo Zeuli, Teresa Gamucci, Marco Nardi, & F. Cognetti. (2001). A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemotherapy and Pharmacology. 47(3). 206–210. 11 indexed citations

20.

Piccart, M., P.F. Bruning, RE Coleman, et al.. (2000). AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282). Ghent University Academic Bibliography (Ghent University). 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact